Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 9:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 26 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Macular Dystrophy, Corneal Clear all
Completed Phase 2 Interventional Results available

Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease

NCT04009668
View directory record Official record
Conditions
FSGS, MCD, Focal Segmental Glomerulosclerosis, Minimal Change Disease
Interventions
adalimumab
Drug
Lead sponsor
University of Michigan
Other
Eligibility
6 Years to 80 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
4
States / cities
Ann Arbor, Michigan • New York, New York • Charlotte, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2024 · Synced Sep 24, 2026, 9:32 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

PIONEER: Intraoperative and Perioperative OCT Study

NCT02423161
View directory record Official record
Conditions
Retinal Detachment, Epiretinal Membrane, Macular Hole, Fuchs Endothelial Dystrophy
Interventions
Not listed
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
750 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2017
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Sep 24, 2026, 9:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Pilot Study of 4-MP to Treat Stargardt Macular Dystrophy

NCT00346853
View directory record Official record
Conditions
Macular Dystrophy, Corneal
Interventions
4-Methylpyrazole, saline
Drug · Other
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 4, 2020 · Synced Sep 24, 2026, 9:32 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of CNTO328 Plus Best Supportive Care in Multicentric Castleman's Disease

NCT01024036
View directory record Official record
Conditions
Multicentric Castleman's Disease
Interventions
Siltuximab, Placebo, Best Supportive Care (BSC)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
11
States / cities
Little Rock, Arkansas • Los Angeles, California • Tampa, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2018 · Synced Sep 24, 2026, 9:32 AM EDT
Completed No phase listed Observational

Potential Research Participants for Future Studies of Inherited Eye Diseases

NCT00559234
View directory record Official record
Conditions
Cataract, Glaucoma, Retinitis Pigmentosa, Macular Degeneration, Strabismus
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 24, 2026, 9:32 AM EDT
Recruiting No phase listed Observational

Nephrotic Syndrome Study Network

NCT01209000
View directory record Official record
Conditions
Minimal Change Disease (MCD), Membranous Nephropathy, Glomerulosclerosis, Focal Segmental
Interventions
Kidney Biopsy
Procedure
Lead sponsor
University of Michigan
Other
Eligibility
Up to 80 Years
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2030
U.S. locations
39
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Sep 24, 2026, 9:32 AM EDT
Recruiting Phase 2 Interventional

Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases

NCT05003986
View directory record Official record
Conditions
Focal Segmental Glomerulosclerosis, Minimal Change Disease, Immunoglobulin A Nephropathy, IgA Vasculitis, Alport Syndrome
Interventions
Sparsentan
Drug
Lead sponsor
Travere Therapeutics, Inc.
Industry
Eligibility
1 Year to 17 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
23
States / cities
Los Angeles, California • Wilmington, Delaware • Miami, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Sep 24, 2026, 9:32 AM EDT
Recruiting No phase listed Observational

International Registry for Patients With Castleman Disease

NCT02817997
View directory record Official record
Conditions
Castleman Disease, Castleman's Disease, Giant Lymph Node Hyperplasia, Angiofollicular Lymph Hyperplasia, Angiofollicular Lymph Node Hyperplasia, Angiofollicular Lymphoid Hyperplasia, GLNH, Hyperplasia, Giant Lymph Node, Lymph Node Hyperplasia, Giant
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Sep 24, 2026, 9:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Cardiac Autonomic Function in Women with Microvascular Coronary Dysfunction

NCT01568177
View directory record Official record
Conditions
Microvascular Coronary Dysfunction
Interventions
Mental Stress Testing, Peripheral Arterial Tonometry (PAT) Testing, Heart Rate Variability (HRV), RESPeRATE Breathing Trial, SPECT cardiac scan with 123I-mIBG and Myoview
Behavioral · Other · Procedure
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 24, 2026, 9:32 AM EDT
Completed Phase 4 Interventional Results available

Extension Study to Gather Data on Effect of Macugen on the Corneal Endothelium

NCT01573572
View directory record Official record
Conditions
Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema
Interventions
pegaptanib sodium injection
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
50 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
4
States / cities
Murrieta, California • Marshalltown, Iowa • West Mifflin, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2021 · Synced Sep 24, 2026, 9:32 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

CEI Van Outreach Screening Study

NCT01510392
View directory record Official record
Conditions
Glaucoma, Macular Disease, Keratoconus
Interventions
OCT imaging, the FDA Cleared iVue
Device
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 89 Years
Enrollment
118 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 11, 2018 · Synced Sep 24, 2026, 9:32 AM EDT
Recruiting No phase listed Observational

Recurrence Post-transplant Observational Study in Focal Segmental Glomerulosclerosis and Minimal Change Disease

NCT05650619
View directory record Official record
Conditions
Focal Segmental Glomerulosclerosis, Minimal Change Disease, FSGS, MCD
Interventions
Biospecimen collection, Data collection
Other
Lead sponsor
University of Michigan
Other
Eligibility
Not listed
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Sep 24, 2026, 9:32 AM EDT
Completed Phase 4 Interventional

Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Cataract Surgery

NCT05626478
View directory record Official record
Conditions
Corneal Edema, Corneal Defect, Anterior Chamber Inflammation, Ocular Pain, Corneal Staining, Visual Outcome, CME - Cystoid Macular Edema
Interventions
Dextenza 0.4Mg Ophthalmic Insert, Prednisolone Acetate 1% Oph Susp, Prolensa 0.07% Ophthalmic Solution
Drug
Lead sponsor
Nicole Fram M.D.
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Sep 24, 2026, 9:32 AM EDT
Recruiting No phase listed Observational

National Ophthalmic Genotyping and Phenotyping Network (eyeGENE (Registered Trademark)), Stage 3 - Expansion of DNA and Data Repositories for Rare Inherited Ophthalmic Diseases

NCT06491615
View directory record Official record
Conditions
Inherited Ophthalmic Diseases, Hypopigmentation Disorder, Corneal Dystrophy, Blue-cone Monochromacy, Best Disease, Aniridia, Albinism
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
1 Day to 120 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2054
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Sep 24, 2026, 9:32 AM EDT
Recruiting Not applicable Interventional

NEPTUNE Match Study

NCT04571658
View directory record Official record
Conditions
Nephrotic Syndrome in Children, Focal Segmental Glomerulosclerosis, Minimal Change Disease, Minimal Change Nephrotic Syndrome, Membranous Nephropathy, FSGS, MCD, MCD - Minimal Change Disease, Alport Syndrome
Interventions
Communication
Other
Lead sponsor
University of Michigan
Other
Eligibility
1 Year to 80 Years
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
16
States / cities
Atlanta, Georgia • Chicago, Illinois • Kansas City, Kansas + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Sep 24, 2026, 9:32 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Anterior Corneal Striae in Hypotony

NCT04023123
View directory record Official record
Conditions
Hypotony Ocular, Cornea Folds and Rupture of Bowman's Membrane Both Eyes, Maculopathy
Interventions
Ophthalmic imaging
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 4, 2020 · Synced Sep 24, 2026, 9:32 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Sirolimus in Previously Treated Idiopathic Multicentric Castleman Disease

NCT03933904
View directory record Official record
Conditions
Castleman Disease, Castleman's Disease, Multicentric
Interventions
Sirolimus
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
2 Years to 80 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
2
States / cities
Little Rock, Arkansas • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 24, 2026, 9:32 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Unlock the Cell: Castleman's Disease Flow Cytometry Study

NCT02853968
View directory record Official record
Conditions
Castleman Disease, Angiofollicular Lymphoid Hyperplasia, GLNH, Hyperplasia, Castleman's Disease, Angiofollicular Lymph Hyperplasia, Giant Lymph Node Hyperplasia
Interventions
Blood draw/buccal swab
Procedure
Lead sponsor
University of Pennsylvania
Other
Eligibility
Not listed
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 25, 2020 · Synced Sep 24, 2026, 9:32 AM EDT
Recruiting Phase 2 Interventional

Atacicept in Multiple Glomerular Diseases

NCT06983028
View directory record Official record
Conditions
pMN, IgAN, Nephrotic Syndrome, MCD, FSGS
Interventions
Atacicept
Drug
Lead sponsor
Vera Therapeutics, Inc.
Industry
Eligibility
2 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Brisbane, California
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Sep 24, 2026, 9:32 AM EDT
Completed Phase 3 Interventional Results available

Steroid Treatment for Kidney Disease

NCT00065611
View directory record Official record
Conditions
Nephrosis, Focal Lipoid Glomerulosclerosis
Interventions
Oral dexamethasone
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
2 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 27, 2011 · Synced Sep 24, 2026, 9:32 AM EDT
Terminated No phase listed Observational

Descemet Membrane Endothelial Keratoplasty vs. Descemet's Stripping With Endothelial Keratoplasty vs. Descemet Stripping Only

NCT04527523
View directory record Official record
Conditions
Cystoid Macular Edema, Fuchs Dystrophy
Interventions
Optical Coherence Tomography
Diagnostic Test
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 12, 2023 · Synced Sep 24, 2026, 9:32 AM EDT
Terminated No phase listed Observational

Tissue Studies of Human Eye Diseases

NCT00001310
View directory record Official record
Conditions
Retinal Disease, Corneal Disease, Diabetic Retinopathy, Uveitis, Age-Related Macular Degeneration
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
3,833 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 8, 2019 · Synced Sep 24, 2026, 9:32 AM EDT
Withdrawn No phase listed Observational

Castleman Disease Collaborative Network Biobank

NCT02871050
View directory record Official record
Conditions
Castleman Disease, Castleman's Disease, Giant Lymph Node Hyperplasia, Angiofollicular Lymph Hyperplasia, Angiofollicular Lymph Node Hyperplasia, Angiofollicular Lymphoid Hyperplasia, GLNH, Hyperplasia, Giant Lymph Node
Interventions
Sample Collection
Other
Lead sponsor
Castleman Disease Collaborative Network
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 30, 2018 · Synced Sep 24, 2026, 9:32 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

DISCOVER Study: Microscope-integrated Intraoperative OCT Study

NCT02423213
View directory record Official record
Conditions
Retinal Diseases, Fuchs Endothelial Dystrophy, Macular Hole, Epiretinal Membrane, Retinal Detachment
Interventions
Not listed
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
2,911 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 2, 2026 · Synced Sep 24, 2026, 9:32 AM EDT